Focus Partners Wealth
JAZZ icon

Focus Partners Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Focus Partners Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.78M Buy
19,842
+4,925
+33% +$1.08M ﹤0.01% 980
2026
Q1 		$2.84M Buy
14,917
+5,150
+53% +$900K ﹤0.01% 1162
2025
Q4 		$1.66M Buy
9,767
+5,224
+115% +$801K ﹤0.01% 1408
2025
Q3 		$599K Sell
4,543
-812
-15% -$97.4K ﹤0.01% 1538
2025
Q2 		$568K Buy
5,355
+732
+16% +$79.5K ﹤0.01% 1377
2025
Q1 		$574K Buy
4,623
+145
+3% +$18.9K ﹤0.01% 1286
2024
Q4 		$551K Buy
+4,478
New +$528K ﹤0.01% 1279
2024
Q3 		– Sell
-4,220
Closed -$450K – 1645
2024
Q2 		$450K Buy
4,220
+183
+5% +$20.1K ﹤0.01% 969
2024
Q1 		$445K Buy
+4,037
New +$494K ﹤0.01% 745

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Focus Partners Wealth's JAZZ Position: Q2 2026 in Review

Focus Partners Wealth increased its Jazz Pharmaceuticals (JAZZ) stake by 33% in Q2 2026, buying an estimated $1.08M and bringing the position to 19,842 shares worth $4.78M. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Focus Partners Wealth first reported a position in JAZZ in Q1 2024 and has held it in 9 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Focus Partners Wealth held 19,842 shares of Jazz Pharmaceuticals worth $4.78M as of Q2 2026.
  • Focus Partners Wealth bought 4,925 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.08M.
  • Jazz Pharmaceuticals made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #980 holding.
  • Focus Partners Wealth first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.